argenx Reports Third Quarter 2023 Financial Results and Provides Business Update - argenx (NASDAQ:ARGX)
$329 million in third quarter global net product salesOn track to submit VYVGART® Hytrulo sBLA for CIDP by year-end 2023 Results from the ADVANCE-IV study published in The Lancet Management to host conference call